Transcranial magnetic stimulation (TMS) is a safe, non-invasive form of neuromodulation that stimulates neurons in the prefrontal cortex with highly focused pulses of magnetic energy. TMS was FDA approved in 2008 for the treatment of depression and in 2018 for the treatment of Obsessive Compulsive Disorder (OCD) in patients who have had limited benefit from medication treatment. Patients generally undergo treatment five times weekly for six weeks followed by a taper phase, however the length of treatment varies on an individual basis. Patients remain awake and alert throughout a treatment session. TMS does not affect other areas of the body, and for most patients it has fewer side effects than medications. In addition, TMS has been reported to be effective for patients with a variety of other illnesses including anxiety disorders, Post Traumatic Stress Disorder (PTSD), chronic pain, and tinnitus, among other conditions. TMS is endorsed by The American Psychiatric Association.